NCT04826341 2026-04-22
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting